SCYNEXIS (SCYX) Trading Down 0%
SCYNEXIS Inc (NASDAQ:SCYX) dropped 0% during mid-day trading on Monday . The company traded as low as $1.99 and last traded at $2.07. Approximately 601,376 shares were traded during mid-day trading, an increase of 40% from the average daily volume of 430,835 shares. The stock had previously closed at $2.07.
SCYX has been the topic of a number of recent research reports. Zacks Investment Research upgraded SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Tuesday, November 14th. Guggenheim initiated coverage on SCYNEXIS in a research note on Tuesday, October 24th. They issued a “buy” rating and a $6.00 target price on the stock. Finally, ValuEngine upgraded SCYNEXIS from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $8.43.
The stock has a market capitalization of $59.12, a price-to-earnings ratio of -2.56 and a beta of 0.36. The company has a current ratio of 7.30, a quick ratio of 7.30 and a debt-to-equity ratio of 0.43.
Several institutional investors and hedge funds have recently modified their holdings of SCYX. National Asset Management Inc. acquired a new position in shares of SCYNEXIS during the second quarter valued at $551,000. DAFNA Capital Management LLC increased its holdings in shares of SCYNEXIS by 32.7% during the second quarter. DAFNA Capital Management LLC now owns 506,900 shares of the company’s stock valued at $907,000 after purchasing an additional 125,000 shares during the period. Dimensional Fund Advisors LP acquired a new position in shares of SCYNEXIS during the third quarter valued at $264,000. Vanguard Group Inc. increased its holdings in shares of SCYNEXIS by 6.0% during the second quarter. Vanguard Group Inc. now owns 868,394 shares of the company’s stock valued at $1,554,000 after purchasing an additional 48,978 shares during the period. Finally, GSA Capital Partners LLP increased its holdings in shares of SCYNEXIS by 33.7% during the second quarter. GSA Capital Partners LLP now owns 176,700 shares of the company’s stock valued at $316,000 after purchasing an additional 44,500 shares during the period. 30.90% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “SCYNEXIS (SCYX) Trading Down 0%” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/scynexis-scyx-trading-down-0/1799011.html.
SCYNEXIS Company Profile
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with Analyst Ratings Network's FREE daily email newsletter.